<SEC-DOCUMENT>0001193125-18-247842.txt : 20180814
<SEC-HEADER>0001193125-18-247842.hdr.sgml : 20180814
<ACCEPTANCE-DATETIME>20180814073034
ACCESSION NUMBER:		0001193125-18-247842
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180814
DATE AS OF CHANGE:		20180814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Iterum Therapeutics plc
		CENTRAL INDEX KEY:			0001659323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38503
		FILM NUMBER:		181014260

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK 2 FLOOR 3, HARCOURT CENTRE
		STREET 2:		HARCOURT STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		(872) 225-6077

	MAIL ADDRESS:	
		STREET 1:		BLOCK 2 FLOOR 3, HARCOURT CENTRE
		STREET 2:		HARCOURT STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Iterum Therapeutics Ltd
		DATE OF NAME CHANGE:	20151124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d577459d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;14, 2018 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Iterum Therapeutics plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38503</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1283148</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Block 2 Floor 3, Harcourt Centre,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Harcourt Street,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dublin
2, Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 903 8920 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT
STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;14, 2018, Iterum Therapeutics plc (&#147;Iterum&#148;) issued a press release announcing certain financial results for its
second quarter ended June&nbsp;30, 2018. A copy of the press release is furnished herewith as Exhibit 99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this
current report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the press release attached as Exhibit 99.1 hereto, is being furnished, but shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be
incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Iterum, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Exhibit&nbsp;No.&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d577459dex991.htm">Press Release of Iterum Therapeutics plc, dated August&nbsp;14, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Iterum Therapeutics plc</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: August&nbsp;14, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Corey N. Fishman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corey N. Fishman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d577459dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g577459g63k07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>FOR IMMEDIATE RELEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DUBLIN and CHICAGO, August&nbsp;14, 2018</B> &#151; Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing
anti-infectives against multi-drug resistant pathogens, today reported financial results for the quarter ended June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Iterum made
significant progress in the second quarter of 2018 with the completion of our IPO, which will allow us to fund our planned Phase 3 clinical trials and regulatory submissions for sulopenem in three indications,&#148; said Corey Fishman, Chief
Executive Officer of Iterum Therapeutics plc. &#147;The first trial is underway for the treatment of women with uncomplicated urinary tract infections, a very large and underserved market. We also plan to initiate two additional Phase 3 trials for
sulopenem in the next few months in complicated urinary tract infections and complicated intra-abdominal infections. We expect <FONT STYLE="white-space:nowrap">top-line</FONT> data from all three trials during the second half of 2019, followed by
our NDA submissions by the end of 2019.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Second Quarter and Recent Highlights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed initial public offering</B>: In May 2018, Iterum closed its initial public offering of ordinary
shares at a public offering price of $13.00 per share. Including shares purchased by the underwriters pursuant to their option exercise, Iterum received net proceeds of approximately $74.2&nbsp;million, net of underwriting discounts and commissions
and offering expenses, from the offering of an aggregate of 6,350,000 shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated a Phase 3 clinical trial of oral sulopenem in uncomplicated urinary tract infections</B>: In August
2018, the company initiated <B>Su</B>lopenem for <B>R</B>esistant <B>E</B>nterobacteriaceae (SURE) 1 trial of oral sulopenem in uncomplicated urinary tract infections (uUTI). The SURE 1 trial is a randomized, multi-center, double-blind study to
measure efficacy, tolerability, and safety of oral sulopenem vs. oral ciprofloxacin for the treatment of uUTI in adult women. Oral sulopenem, if approved, could be the first antibiotic approved for uUTI in over 20 years. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Presented data at ASM Microbe</B>: In June 2018, Iterum presented data on the prevalence of resistant
infections and <I>in vitro</I> activity of sulopenem at the American Society of Microbiology (ASM) MICROBE meeting in Atlanta. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Second Quarter 2018 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, Iterum had cash, cash equivalents and short-term investments of $135.3&nbsp;million and approximately 14.2&nbsp;million shares
outstanding. Iterum expects that its cash, cash equivalents and short-term investments, along with its available borrowings, will be sufficient to fund operations through the fourth quarter of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the full year 2018, operating expenses are expected to be approximately <FONT STYLE="white-space:nowrap">$90-95&nbsp;million,</FONT> which includes the
milestone payments owed to Pfizer on first patient dosed in a Phase 3 trial with oral and IV sulopenem of $7.5&nbsp;million for each product (or $15&nbsp;million total). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses for the second quarter of 2018 were $13.7&nbsp;million compared to $5.3&nbsp;million for the same period in 2017. The
$8.4&nbsp;million increase was primarily due to the increase in clinical trial expenses and clinical trial materials as Iterum prepared for the initiation of its three Phase 3 clinical trials in the second half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the second quarter of 2018 were $1.9&nbsp;million compared to $1.1&nbsp;million for the same period in 2017. This
increase was primarily due to increased headcount to support research and development efforts, increased costs associated with operating as a public company and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum reported a net loss for the second quarter of 2018 of $15.7&nbsp;million compared to a net loss of $6.3&nbsp;million for the same period in 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Iterum Therapeutics plc </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics plc is
a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and
life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations that has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received QIDP designations for its oral and IV formulations for the treatment of uUTI, complicated urinary tract infection and complicated
intra-abdominal infection. For more information, please visit http://www.iterumtx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding financial guidance
for 2018, expectations regarding future revenue, expenses, cash flows and net income or loss, the development, therapeutic and market potential of sulopenem, the timing, progress and results of clinical trials, and the expected timing of NDA
filings. In some cases, forward-looking statements can be identified by words such as &#147;may,&#148; &#147;believes,&#148; &#147;intends,&#148; &#147;seeks,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;estimates,&#148;
&#147;expects,&#148; &#147;should,&#148; &#147;assumes,&#148; &#147;continues,&#148; &#147;could,&#148; &#147;will,&#148; &#147;future,&#148; &#147;potential&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum Therapeutics&#146; actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical
facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum Therapeutics&#146; control, including the uncertainties inherent in the initiation and conduct of clinical trials, clinical trial
patient enrollment, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, commercialization plans and timelines, if approved, the actions of third-party clinical research
organizations, suppliers and manufacturers and other factors discussed under the caption &#147;Risk Factors&#148; in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) on or about&nbsp;August 14, 2018, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum Therapeutics&#146; beliefs and assumptions only as of the date of this press release. Except as
required by law, Iterum Therapeutics assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new
information becomes available in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeff Schaffnit </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">312-778-6076</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@iterumtx.com </U></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statement of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income / (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income / (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to ordinary shareholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(82.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average ordinary shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,085,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,148,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheet Data </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,470</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, convertible preferred shares and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,470</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g577459g63k07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g577459g63k07.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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()MO5BTQ'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
